Author

Al Spada

Institution: Conatus Pharmaceuticals (United States)

Observed institution: Conatus Pharmaceuticals (United States)

OpenAlex ID: A5085994310

Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non‐alcoholic fatty liver disease

2018 · Mitchell Shiffman, Bradley Freilich, et al. · Alimentary Pharmacology & Therapeutics · 115

Emricasan, a pan-caspase inhibitor, improves survival and portal hypertension in a murine model of common bile-duct ligation

2018 · Akiko Eguchi, Yukinori Koyama, et al. · Journal of Molecular Medicine · 30

Works count: 2

Citation count: 145

H-index: 2

I10-index: 2